ED Coding & Reimbursement Alert - 2004 Issue 39
DRUG REIMBURSEMENT: Good News: You Soon Can Use 14 New Anti-Cancer Drug Codes
Subscribe or sign in to view the full article.
Article Overview
This premium article explains Medicare reimbursement updates affecting oncology practices, including CMS approval of new drug administration coding, payment considerations tied to infusion and medication preparation, and the agency’s handling of adverse drug reaction management. It also covers concerns raised by oncology organizations and coding professionals about how the changes may affect physician office cancer care, claim handling, and access to treatment. The article is relevant to oncology coders, billing staff, practice managers, and anyone following Medicare payment policy for drug administration services.
Why This Topic Matters
These policy changes can affect how cancer practices report drug administration services, how Medicare pays for those services, and whether existing billing pathways remain practical for managing treatment reactions. The article also highlights operational and access-to-care implications for physician offices treating oncology patients.
Article Sections
-
CMS approval of new drug administration payment codes
Explains the Medicare policy update, the timing of the new codes, and the general reimbursement areas they are intended to address.
-
Payment calculation and oncology organization response
Summarizes how CMS described the payment inputs and notes the reaction from oncology stakeholders seeking more clarity on the final amounts.
-
Managing adverse drug reactions without new codes
Describes CMS’s approach to drug-reaction management and the broader billing options referenced for those services.
-
Billing and claims processing concerns
Reviews concerns about claim edits, denials, and documentation-related handling of certain visits and services.
-
Bundling issues and drug pricing policy
Covers Medicare bundling of some drug administration services with evaluation and management visits and discusses the broader pricing policy issue raised at the end of the article.
What You Will Learn
- The general scope of CMS’s oncology drug administration reimbursement update
- How payment methodology changes can affect physician office cancer care
- Why oncology groups and coders are concerned about claim processing and denials
- How Medicare policy choices may affect reimbursement for drug-related services
- What broader pricing and access concerns were raised in connection with the update
Who Should Read This
- Oncology coders
- Medical billers
- Physician practice administrators
- Oncology office staff
- Health policy analysts
- Medicare reimbursement specialists
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com